ArticlePloS one2026

Correction: Economic evaluation of atezolizumab in combination with bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer in China: A cost-effectiveness analysis.

Shuo Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.